Andrade Robert 4

What Happened
Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), exercised stock options to acquire 13,072 shares at a strike price of $5.10 per share, for a total exercise cost of $66,667. The Form 4 also reports a matching disposition of a derivative interest for the same number/value of shares on 2026-03-26 (transaction code M).

Key Details

• Transaction date: 2026-03-26. Transaction code M = option exercise.
• Shares: 13,072 shares acquired at $5.10 per share; total = $66,667. A matching disposition of 13,072 (derivative) is also reported.
• Footnote: Shares were acquired through exercise of an option contract with strike $5.10 and expiration June 27, 2027 (Footnote F1).
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Filing timeliness: Reported on 2026-03-26 (same day as the transaction); no late filing indicated.

Context
The report shows both an exercise and a derivative disposition for the same amount. That pattern commonly reflects an option exercise paired with an immediate disposition (for example, a cashless exercise or same-day sale), but the filing does not specify whether the acquired shares were sold in the open market, withheld for taxes, or otherwise transferred. This is a routine insider option exercise disclosure and should be read as factual reporting of the transaction rather than a statement of intent or view on the company.